Moulin 2006

1 Treatments

**Studied treatment** benfluorex 450 mg/day

**Control treatment** placebo

**Concomittant treatments**

**Age (years)**

**female (%)**

2 Patients

**Patients** Type 2 diabetic patients with HbA1c between 7-10% with maximum tolerated sulfonylurea dose and with a contraindication to or poor tolerance of metformin

**Inclusion criteria**

**Exclusion criteria**

**fracture definition**

3 Methods

**Blinding** double-blind

**Design** Parallel groups

**Centers**

**Geographical area**

**Sizes** 165/160

**Diabetes duration (years)**

**BMI (kg/m²)**

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>weight (kg)</td>
<td>-/165</td>
<td>-/160</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c &lt;= 7 HbA1c &lt;= 6.5</td>
<td>-/165</td>
<td>-/160</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>-/165</td>
<td>-/160</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References